Abstract
ABSTRACTPf is a filamentous bacteriophage integrated in the chromosome of most clinical isolates ofPseudomonas aeruginosa. Under stress conditions, mutations occurring in the Pf genome result in the emergence of super-infective variants of Pf (SI-Pf) that are capable of circumventing phage immunity; therefore SI-Pf can even infect Pf-lysogenizedP. aeruginosa. Herein, we identified specific mutations located between the repressor and the excisionase genes that result in the emergence of SI-Pf. Based on these findings, we genetically engineered a SI-Pf (eSI-Pf) and tested it as a phage therapy tool for the treatment of life-threateningP. aeruginosainfection of burns caused by strain PAO1. eSI-Pf was able to infect PAO1 biofilms formed in vitro on polystyrene and inhibited their formation when at high concentration. eSI-Pf also infected PAO1 present in burned skin wounds on mice but was not capable of maintaining a sustained reduction in bacterial burden beyond 24 hours. Importantly, and despite not lowering CFU/g of burn skin tissue, eSI-Pf treatment completely abolished the capability ofP. aeruginosato disseminate from the burn site to internal organs. Over the course of 10 days, this resulted in bacterial clearance and survival of all treated mice. We determined that eSI-Pf induced a small colony variant ofP. aeruginosathat was unable to disseminate systemically in our burned mouse model during acute infection. Our results suggest that eSI-Pf has potential as a phage therapy against highly recalcitrant antimicrobial resistantP. aeruginosainfections of burn wounds.IMPORTANCEPseudomonas aeruginosais a major cause of burn related infections. It is also the most likely bacterial infection to advance to sepsis and result in burn-linked death. Frequently,P. aeruginosastrains isolated from burn patients display a multidrug resistant phenotype necessitating the development of new therapeutic strategies and prophylactic treatments. In this context, phage therapy using lytic phages has demonstrated exciting potential in the controlP. aeruginosainfection. However, lytic phages have a set of drawbacks during phage therapy including the induction of bacterial resistance and limited bacteria-phage interactions in vivo. Here we propose an alternative approach to interfere withP. aeruginosapathogenesis in a burn infection model, i.e., using an engineered super-infective filamentous phage. Our study demonstrates that treatment with the engineered Pf phage can prevent sepsis and death in a burn mouse model.
Publisher
Cold Spring Harbor Laboratory
Reference50 articles.
1. Jurado-Martin I , Sainz-Mejias M , McClean S. 2021. Pseudomonas aeruginosa: An Audacious Pathogen with an Adaptable Arsenal of Virulence Factors. Int J Mol Sci 22.
2. Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence;Front Cell Infect Microbiol,2017
3. Anonymous. WHO | WHO publishes list of bacteria for which new antibiotics are urgently needed. WHO Available at: http://www.who.int/mediacentre/news/releases/2017/bacteria-antibiotics-needed/en/. (Accessed: 14th June 2017).
4. Batinovic S , Wassef F , Knowler SA , Rice DTF , Stanton CR , Rose J , Tucci J , Nittami T , Vinh A , Drummond GR , Sobey CG , Chan HT , Seviour RJ , Petrovski S , Franks AE. 2019. Bacteriophages in Natural and Artificial Environments. Pathogens 8.
5. Phage therapy: Current status and perspectives